SCHEMBL9913611

SCHEMBL9913611

COc1ccc(CNc2ncnc3c2ccn3[C@@H]2C[C@H](CNC3CC(CCC4OC(C)O4)C3)[C@@H](O)[C@H]2O)c(OC)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRMT5 O14744 10/20 0.41
▸ WDR77 Q9BQA1 6/20 0.41
▸ ALDH1A1 P00352 6/20 0.39
▸ CYP1A2 P05177 6/20 0.39
▸ CYP3A4 P08684 6/20 0.39
▸ CYP2C19 P33261 6/20 0.39
▸ CLK4 Q9HAZ1 6/20 0.39
▸ TSHR P16473 5/20 0.39
▸ HSD17B10 Q99714 5/20 0.39
▸ CYP2D6 P10635 5/20 0.39
▸ CYP2C9 P11712 4/20 0.39
▸ USP2 O75604 4/20 0.39
▸ LMNA P02545 4/20 0.39
▸ MEN1 O00255 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ MAPK1 P28482 3/20 0.39
▸ HIF1A Q16665 3/20 0.39
▸ ALOX15 P16050 2/20 0.38
▸ METTL3 Q86U44 1/20 0.37
▸ ADORA3 P0DMS8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9913615 0.88 CYP1A2 (0.37) PRMT5WDR77ALDH1A1CYP1A2CYP3A4
SCHEMBL9107052 0.85 MAPT (0.41) PRMT5WDR77ALDH1A1CYP1A2CYP3A4
SCHEMBL9110010 0.81 PRMT5 (0.47) PRMT5WDR77ALDH1A1CYP1A2CYP3A4
SCHEMBL10248935 0.78 CYP1A2 (0.38) PRMT5WDR77ALDH1A1CYP1A2CYP3A4
SCHEMBL9104849 0.78 CYP1A2 (0.37) PRMT5WDR77ALDH1A1CYP1A2CYP3A4
SCHEMBL9104853 0.78 CYP1A2 (0.37) PRMT5WDR77ALDH1A1CYP1A2CYP3A4
SCHEMBL9913561 0.78 CYP1A2 (0.37) PRMT5WDR77ALDH1A1CYP1A2CYP3A4
SCHEMBL9913543 0.77 CYP1A2 (0.35) PRMT5WDR77ALDH1A1CYP1A2CYP3A4
SCHEMBL9288247 0.76 MAPT (0.39) PRMT5WDR77ALDH1A1CYP1A2CYP3A4
Ammonia Solution, Strong SCHEMBL9109945 0.76 MAPT (0.38) PRMT5WDR77ALDH1A1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012075381-A1 SUBSTITUTED PURINE AND 7 - DEAZAPURINE COMPOUNDS AS MODULATORS OF EPIGENETIC ENZYMES Epizyme, Inc. (US) 2012-06-07 — — WO disclosed
US-20120142625-A1 Substituted Purine And 7-Deazapurine Compounds Epizyme, Inc. (US) 2012-06-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142625-A1 Substituted Purine And 7-Deazapurine Compounds TPMT, DIMT1, DAZAP1 PRMT5 37/4885WDR77 32/4885ALDH1A1 592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback